The transaction, expected to close in the second half of 2026, signals Novartis’ continued push to strengthen its oncology pipeline, particularly in the fast-evolving field of antibody-drug conjugates (ADCs), a class of targeted cancer therapies designed to deliver potent drugs directly to tumour cells.
Deal Structure: $1.1 Billion Upfront, With Milestone Upside
Under the agreement, Novartis will pay $1.1 billion upfront, with an additional $400 million tied to regulatory and development milestones.
The acquisition gives the Swiss drugmaker access to Myricx Bio’s proprietary ADC platform, which focuses on developing novel payload mechanisms aimed at improving how cancer drugs overcome resistance in tumours.
Why ADCs Are Becoming Central to Cancer Treatment
ADCs have rapidly emerged as one of the most promising innovations in oncology, combining the precision of targeted therapy with the potency of chemotherapy.
As Novartis executives noted, the space is still evolving and requires further innovation to fully unlock its potential.
“ADCs have become an important part of cancer treatment, but there remains a clear need for new payload mechanisms to overcome resistance and expand their impact for patients,” said Fiona Marshall, president of biomedical research at Novartis.
Her comments underscore a broader industry challenge: while ADCs are effective in many cancers, resistance and durability of response remain key hurdles.
Novartis Expands Its Oncology Strategy
The deal reflects Novartis’ broader strategy of scaling high-impact therapeutic platforms, particularly in oncology, where competition among global drugmakers has intensified.
Marshall added that the acquisition aligns with the company’s approach of building on successful innovation models.
“This proposed acquisition reflects our strategy to scale innovative platforms, as we have with radioligand therapies, to deliver more durable, transformative treatments for patients.”
Novartis has previously invested heavily in radioligand therapies, a precision treatment approach that delivers targeted radiation to cancer cells, and sees ADCs as a complementary pillar in its long-term cancer strategy.
A High-Stakes Race in Cancer Innovation
The acquisition comes at a time when global pharmaceutical companies are aggressively competing for leadership in next-generation oncology treatments.
ADCs, once a niche field, are now seen as one of the fastest-growing segments in cancer drug development, attracting significant investment and deal activity across the industry.
For Novartis, the Myricx Bio deal represents not just a portfolio expansion, but a strategic bet on the future of precision oncology—where treatments are increasingly designed to be both more effective and less toxic than traditional chemotherapy.